The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 16.4% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 25%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (5 analysts) rates it none, with a mean price target of $26.
Azenta, Inc. AZTA
Clears both ethical standards
An entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.
In plain words · Azenta, Inc.
read at $26.29
Azenta, Inc. holds its Markup at $26.29.
- PHPhase · the trend structure carries the Markup label
- INInsiders · no filings inside 60 days, left as found
- POPositioning · no disclosures inside 60 days, left as found
- OPOptions · no verdict drawn today, left as found
- SCScreen · passes the values gate
- edge confirmed
- edge broken
- edge forming
Each arm is one independent read. Conviction is not a single call, it is how many edges converge.
The investor read · the season, not the day
| Phase | Markup |
| Quantitative state | The statistical read favours the sellers, held for 15 days |
| Price | $26.29 |
| Valuation | N/A trailing · 42.82 forward price to earnings |
| Values screen | PASS · score 70.0 |
| Beta | 1.37 |
The opportunity · what the numbers say it is worth
Price history & projections · where it has been, where the models see it going
The valuation journey · where the price sits against fair value and the Street
Green marks levels above today's price, red below; the shaded band is the gap between the price and our fair value.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish — a quality-at-a-fair-price name rather than a deep-value one.
| Revenue growth | 1.00% |
| Profit margin | -29.06% |
| Debt to equity | 3.58 |
| Analyst consensus | Buy · 5 covering |
Fair value and rating are our own model estimates; target range reflects third-party analyst estimates. Analysis, not advice.
The values screen, explained · five checks, plain English
This company clears both standards. There are two widely recognised ways to check whether a company is suitable for a Muslim investor. Here is how it did on each:
Used by most halal investing apps ✓ PASSES
The one Titan applies ✓ PASSES
What these two standards are, and how they differ →
- Business activity Its core business isn't built on prohibited lines — no gambling, alcohol, tobacco, weapons, or interest-based lending. Pass
- Debt load Interest-bearing debt is of its assets, above the one-third ceiling the screen allows. Fail
- Interest-bearing cash Interest-bearing cash and securities are of assets, above the one-third limit. Fail
- Receivables Money owed to the company is of assets, above the 49% limit. Fail
- Revenue purity Only 0.0% of revenue comes from non-compliant sources — under the 5% line. Pass
Every security is read against two recognised standards: our stricter asset-based screen (ratios measured against total assets) and the more widely used market-value standard (measured against market capitalisation). Where they agree we say so plainly; where they part ways — almost always on the debt check — we show both readings and mark it, because that disagreement is the finding, not a fault. We report the score; you and your scholar make the call.
The business, in plain words · what the numbers mean
Sample handler priced far beyond its real worth
Picture a firm that helps labs store and manage millions of biological samples across continents. Azenta does that job, yet the shares sit well above any sensible price. At twenty six dollars the stock carries a forward multiple of forty three times earnings for revenue that is barely growing and profits that remain deep in the red.
The gap to our fair value of seventeen dollars leaves a thirty six percent shortfall with no margin of safety. One percent top line growth and a negative twenty nine percent profit margin do not support the current valuation, even if five analysts still carry buy notes with a twenty eight dollar median target. Ethical screens clear, but that alone does not turn a stretched price into an opportunity.
High multiples on weak returns on equity and thin growth often signal a value trap rather than a bargain. Currency moves and life science spending cycles add further uncertainty. Analysis, not advice.
| Forward P/E | 42.8x expensive even after accounting for its growth |
| Revenue growth | 1.0% slow but positive growth |
| Profit margin | -29.1% currently unprofitable |
| Return on equity | -6.8% not currently earning a positive return on equity |
| Debt to equity | 3.58 heavy leverage — higher risk if revenue softens |
| Current ratio | 2.83 comfortably covers its short-term bills |
| Beta | 1.37 moves a little more than the market |
| Market cap | $1.2B |
| Employees | 2,900 |
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day; it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Related securities · others in AZTA's space worth a look
Screened names in the same industry · explore each on its own page.
Where & how to trade · wherever in the world you are
AZTA trades on Nasdaq. As a US-listed security it is accessible through almost any international broker offering US markets. New to this, or investing from outside the US? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The trader read · the latest dated commentary
The dated journal · newest first, never edited
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 25%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (5 analysts) rates it none, with a mean price target of $26.
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
What holding actually paid · price plus dividends
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $17.95 | +26.6% | · | $1,266 | +26.6% |
| 2 months | $22.21 | +2.3% | · | $1,023 | +2.3% |
| 3 months | $21.37 | +6.4% | · | $1,064 | +6.4% |
| 6 months | $37.50 | -39.4% | · | $606 | -39.4% |
| 1 year | $30.42 | -25.3% | · | $747 | -25.3% |
| 2 years | $54.94 | -58.6% | · | $414 | -58.6% |
| 3 years | $45.13 | -49.6% | · | $504 | -49.6% |
| 5 years | $99.42 | -77.1% | $0.20 | $231 | -76.9% |
Historical returns from market close data. Past performance does not guarantee future results.